ABSTRACT
The new type of coronavirus pneumonia (COVID-19) is raging around the world, and the number of diagnoses and deaths continues to rise, and there is still no specific treatment drug. Chloroquine is a traditional medicine for the treatment of malaria and autoimmune diseases. It has shown initial efficacy in the treatment of COVID-19 and has attracted much attention. Hydroxychloroquine is a derivative of chloroquine, and its clinical drug safety is higher than that of chloroquine. It is listed by the World Health Organization as one of the 4 candidate trial drugs for the treatment of COVID-19 , Has also been included in the trial of the sixth and seventh editions of the COVID-19 treatment plan by the National Health Commission of China. However, the clinical efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19 is still very controversial, and sufficient Clinical data supports its use as a recommended drug for the treatment of COVID-19. In order to have a clearer understanding of chloroquine and hydroxychloroquine, this article briefly summarizes the pathological changes and treatment options of COVID-19, focusing on the efficacy of hydroxychloroquine in clinical trials and an in-depth analysis The potential causes and possible mechanisms of the different results of hydroxychloroquine in clinical trials, and the potential therapeutic effects of anisodamine and the antiviral drug remdesivir and psychological interventions are discussed, which are important for the rationalization of COVID-19 treatment options Reference value.